Company / Net Income
Inhibikase Therapeutics, Inc. Net Income History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$19.0M
FY2024
5-year range
-$19.0M / -$2.8M
FY2021-FY2024
Trend
-5.4%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Net Income has declined for 3 consecutive years, from -$3M in FY2021 to -$19M in FY2024.
Based on SEC 10-K filings.
-$19M in FY2024.
Declined from -$15M to -$19M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Inhibikase Therapeutics, Inc.'s net income has declined for 3 consecutive years.
- In FY2024, net income decreased 5.4% year-over-year.
Company context
Key Data Points
- Altman Z-Score 0.11 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$19.0M | -5.4% |
| FY2023 | -$18.1M | -22.1% |
| FY2022 | -$14.8M | -419.2% |
| FY2021 | -$2.8M | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026